Почетна страница22UA • FRA
add
BioNTech SE - ADR
Прет. посл. цена
90,95 €
Дневен опсег
90,20 € - 92,85 €
Годишен опсег
69,70 € - 124,60 €
Пазарна капитализација
24,05 милј. USD
Просечен обем
811,00
Сооднос Ц/З
-
Принос од дивиденда
-
Примарна берза
NASDAQ
Во вестите
Информации
BioNTech SE is a global biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
Главен извршен директор
Основана на
2008
Веб-сајт
Вработени
6.772